External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Immunology Autoimmune disease

Autoimmune disease

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Real-World Effectiveness of Omalizumab▼ in Patients Treated for Chronic Spontaneous Urticaria
This poster examined the real-world effectiveness of omalizumab▼ in reducing oral corticosteroid use in patients with chronic spontaneous urticaria.
Immunology Autoimmune disease ACAAI-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Impact of Baseline Angioedema and IgE on Response to Omalizumab▼ in Chronic Spontaneous Urticaria
This poster examined the impact of baseline angioedema status and IgE levels on response to omalizumab▼ in patients with chronic spontaneous urticaria.
Immunology Autoimmune disease ACAAI-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 9 / Roche and Genentech
Omalizumab▼ Use in Patients with Chronic Spontaneous Urticaria: A Real-World Survey in the United States
This poster examined the real-world use of omalizumab▼ by allergists, dermatologists, and primary care physicians, in patients with chronic spontaneous urticaria.
Immunology Autoimmune disease ACAAI-2023
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.